Fair Value of Financial Assets and Liabilities (Details) - USD ($)	Sep. 23, 2025	Feb. 23, 2024	Jun. 30, 2026	Dec. 31, 2025	Jul. 03, 2024	Feb. 29, 2024	Dec. 06, 2021	May 04, 2020
Fair Value of Financial Assets and Liabilities [Line Items]
Investment share amount	$ 3,740
Consolidated investment			$ 36,819	$ 36,819
Class C Common Share [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Price per share (in Dollars per share)	$ 0.036
Class N common stock [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Price per share (in Dollars per share)	$ 0.034
Maximum [Member] \| Class N common stock [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Percentage of voting rights	5.00%
Minimum [Member] \| Class N common stock [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Percentage of voting rights	3.00%
Zylö Therapeutics [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Investment in shares (in Shares)	110,000
Investment share amount					$ 79
Price per share (in Dollars per share)			$ 0.167		$ 0.0036
Zylö Therapeutics [Member] \| Class B Common Stock [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Investment in shares (in Shares)		22,000	220,000	220,000		220,000	100,000	120,000
Investment share amount			$ 36,740	$ 36,740		$ 36,740		$ 60,000
Reverse stock split		1-for-10
Zylö Therapeutics [Member] \| Class N common stock [Member]
Fair Value of Financial Assets and Liabilities [Line Items]
Reverse stock split	1-for-2